Advancing a new generation
of fine-tuned neuromedicines
Our platform enables us to develop novel, differentiated GABAA positive allosteric modulators to precisely treat neurological disorders like Essential Tremor, epilepsy and anxiety
Pagliuca
Harvard
Life Lab
OUR STORY
Our team has dedicated their careers to neuromedicine. We coalesced to advance scientific innovations that help patients with neurological disorders live longer, healthier lives.
The idea was born at Prof. Kevin Hodgetts' Laboratory for Drug Discovery in Neuroscience at the Brigham and Women's Hospital, when Dr. Hodgetts and Dr. Dario Doller saw the opportunity to harness allosteric modulation to develop a new generation of GABAA small molecule therapies.
We are now advancing small molecules to treat Essential Tremor (ET), epilepsy, anxiety, and other neurological disorders.
Our methodology
Next-gen
We are building on 160+ years of GABAA research to develop next-gen, differentiated GABAA PAMs that provide efficacy without side-effects.
Translatable
We focus on validated biological targets, with strong translational assays and efficient route to clinical proof-of-mechanism where current treatments fail to address patient needs.
Fine-Tuned
Our lead small molecules are fine-tuned GABAA modulators that can restore healthy receptor function while avoiding over-activation.
Our First Therapies
We have achieved in vivo proof-of-concept in mice, and are close to identifying a development candidate to treat Essential Tremor.
Our compounds show strong activity in epilepsy models, which we are scaling up
Meet the Team
We have dedicated our careers to advancing scientific innovations to help patients live longer, healthier lives.
Our Scientific Advisory Board
Our team has developed 50+ clinical and 10 marketed drugs
Recognitions
Nucleate Venture Prize
Awarded pre-seed funding from Pillar VC via NVP, 1 of 200 teams
Blavatnik Therapeutics Grant
Founding lab supported by Blavatnik grant funding for this project from 2022-2024
Harvard Business School
Semi-finalists in the 2023 HBS NVC pitch competition
Nucleate Activator Program
Semi-finalists in the 2023 Nucleate Activator Program final pitch showcase in Boston
iLab Grant Award
Awarded grant funding by the iLab in 2023 and 2024
Harvard Innovation Lab
Semi-finalists 2023 and
Finalists 2024 in the Harvard iLab’s PIC, 5 of 400+ teams
MIT SHIP Competition
Semi-finalists in the 2024 MIT SHIP competition, 8 of 300+ teams
Current treatments are worse than the disease itself
- Patients, physicians and caregivers struggling with Essential Tremor (ET)
Indication #1: Essential Tremor
Essential Tremor is widespread and highly debilitating
Yet ET remains significantly underreported and undertreated
We are thrilled to advance the first novel treatment to help ET patients, their families and caretakers in over half a century.
Please connect to learn more - we are excited to engage with the ET community!
Get in Touch
Modulate Bio
Pagliuca Harvard Life Lab
127 Western Avenue, Allston, MA 02134